Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.

Trial Details

NCT ID
NCT05623319
Phase
PHASE2
Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pembrolizumab/Olaparib
Locations (sample)
  • Meldola, Forlì Cesena, Italy|44.12775,12.0626
  • Monza, Monza E Brianza, Italy|45.58005,9.27246
  • Pesaro, Pesaro Urbino, Italy|43.90921,12.9164
  • Bari, Italy|41.12066,16.86982
  • Bologna, Italy|44.49381,11.33875

Key Eligibility Criteria

  • The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  • Male/female participants who are at least 18 years of age on the day of signing informed consent.
  • Cytologically/histologically confirmed diagnosis of SCLC per the Veterans Administration Lung Study Group (VALG) staging system will be enrolled in…
  • Possibility of obtaining tissue sample, via a biopsy of the primary tumour or metastatic tumour tissue, within the 6 weeks prior to study entry. An…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →